An outbreak of group A streptococcal infection among health care workers

Clinical Infectious Diseases

Volumn 35, Issue 11, 2002, Pages 1353-1359

  Kakis, Anthony ^a   Gibbs, Laurel ^a   Eguia, Jose ^b   Kimura, Joe ^b   Vogelei, Diane ^a   Troup, Nancy ^c   Stevens, Dennis ^d,e   Kaplan, Edward L ^f   Johnson, Dwight R ^f   Conte Jr , John E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d Boise VA Medical Center   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; IMMUNOGLOBULIN; M PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; PENICILLIN G; PHENETICILLIN; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN;

ADULT; ANAMNESIS; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BLOOD CULTURE; BREAST DISCHARGE; BREAST LESION; BREAST TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATITIS; DIARRHEA; DISEASE TRANSMISSION; DNA FINGERPRINTING; DRUG HYPERSENSITIVITY; EPIDEMIC; ESCHERICHIA COLI; FEMALE; HEALTH CARE PERSONNEL; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; PATIENT; PHARYNGITIS; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; SKIN BIOPSY; SPECIES INVASION; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SYMPTOM; TREATMENT PLANNING;

ADULT; ANTI-BACTERIAL AGENTS; DISEASE OUTBREAKS; FEMALE; HEALTH PERSONNEL; HUMANS; MALE; MIDDLE AGED; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

EID: 0036903090     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344279     Document Type: Article

References (23)

1. Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994; 124:9-16.
2. Veasy LG, Wiedmeier SE, Orsmond GS, et al. Resurgence of acute rheumatic fever in the intermountain area of the United States. N Engl J Med 1987; 316:421-7.
3. Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317:146-9.
4. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989; 321:1-7.
5. Communicable Disease Surveillance Center. Surveillance of streptococcal infections: Bacteremia and meningitis 1975-88. Commun Dis Rep 1990; 26:3-4.
6. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome: A retrospective population-based study. JAMA 1993; 269:384-9.
7. Schwartz B, Facklam RR, Breiman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336:1167-71.
8. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166:374-82.
9. Schwartz B, Elliott JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992; 15:277-84.
10. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335:547-54.
11. Zurawski CA, Bardsley M, Beall B, et al. Invasive group A streptococcal disease in metropolitan Atlanta: A population-based assessment. Clin Infect Dis 1998; 27:150-7.
12. Sharkawy A, Low DE, Saginur R, et al. Severe group A streptococcal soft-tissue infections in Ontario: 1992-1996. The Ontario Group A Streptococcal Study Group. Clin Infect Dis 2000; 34:454-60.
13. Ramage L, Green K, Pyskir D, Simor AE. An outbreak of fatal nosocomial infections due to group A streptococcus on a medical ward. Infect Control Hosp Epidemiol 1996; 17:429-31.
14. Garner JS. Guideline for isolation precautions in hospitals. Part I. Evolution of isolation practices, Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996; 24:24-31.
15. Johnson DR, Kaplan EL, Sramek J, et al. Laboratory Diagnosis of Group A Streptococcal Infections. Geneva: World Health Organization, 1996.
16. Rotta J, Krause RM, Lancefield RC, Everly W, Lackland H. New approaches for the laboratory recognition of M types of group A streptococci. J Exp Med 1971; 134:1298-315.
17. Johnson DR, Kaplan EL. Microtechnique for serum opacity factor characterization of group A streptococci adaptable to the use of human sera. J Clin Microbiol 1988; 26:2025-30.
18. Stevens DL, Salmi DB, McIndoo ER, Bryant AE. Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among Streptococcus pyogenes causing streptococcal toxic shock syndrome. J Infect Dis 2000; 182:1117-28.
19. DiPersio JR, File TM Jr, Stevens DL, Gardner WG, Petropoulos G, Dinsa K. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996; 22:490-5.
20. Gerber MA. Comparison of throat cultures and rapid strep tests for diagnosis of streptococcal pharyngitis. Pediatr Infect Dis J 1989; 8:820-4.
21. Outbreak of invasive group A Streptococcus associated with varicella in a childcare center - Boston, Massachusetts, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:944-8.
22. Prevention of invasive group A streptococcal disease among household contacts of case-patients: Is prophylaxis warranted? The Working Group on Prevention of Invasive Group A Streptococcal Infections. JAMA 1998; 279:1206-10.
23. Chaudhary S, Bilinsky SA, Hennessy JL, et al. Penicillin V and rifampin for the treatment of group A streptococcal pharyngitis: A randomized trial of 10 days penicillin vs. 10 days penicillin with rifampin during the final 4 days of therapy. J Pediatr 1985; 106:481-6.